ArticleFrontiers in oncology2026
Integrating MRI habitat heterogeneity and peritumoral radiomics into a nomogram for optimized risk stratification in locally advanced rectal cancer: a multicenter study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial for "MRI Habitat Analysis for Preoperative Prediction of Perineural Invasion and Prognostic Stratification in Rectal Cancer".Journal of magnetic resonance imaging : JMRI · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Risk stratification is essential for optimizing treatment in locally advanced rectal cancer (LARC), particularly for identifying suitable candidates for total neoadjuvant therapy (TNT). Conventional MRI-based staging has limited sensitivity in capturing tumor microenvironment (TME) heterogeneity, which may lead to undertreatment of high-risk patients or overtreatment of low-risk subgroups. This study aimed to develop a nomogram integrating MRI-based habitat heterogeneity and peritumoral radiomics to improve risk stratification in LARC. Methods: A multicenter retrospective cohort of 290 LARC patients (training set, n=178; external test set, n=112) was analyzed. Tumor volumes and peritumoral regions (1, 2, and 3 mm margins) were delineated on high-resolution MRI scans using 3D Slicer. Habitat heterogeneity was quantified via K-means clustering (k=3) of intratumoral radiomic features. Radiomic features were filtered and reduced using LASSO regression. Logistic regression (LR) and support vector machine (SVM) classifiers were used to build intratumoral, peritumoral, and habitat models. The better-performing model between the intratumoral and habitat models was combined with the optimal peritumoral model and clinical variables to construct a nomogram. Calibration curves assessed agreement between predicted and observed high-risk LARC. Model performance was evaluated using area under the curve (AUC), sensitivity, specificity, and decision curve analysis (DCA). Results: LR classifiers outperformed SVM classifiers and were therefore selected for the intratumoral, peritumoral, and habitat models. The habitat and peritumoral (3 mm) models showed superior performance compared with the intratumoral and peritumoral (1 mm) models and were integrated with clinical variables into a nomogram. The nomogram achieved excellent performance in both training (AUC, 0.928) and test cohorts (AUC, 0.817), surpassing single-feature models. Calibration curves demonstrated good agreement between predicted and observed high-risk LARC. DCA showed the nomogram provided higher net benefit across a broad range of threshold probabilities. Conclusion: By characterizing the spatial heterogeneity of the tumor microenvironment, an MRI-derived nomogram integrating habitat heterogeneity, peritumoral (3 mm) radiomic features, and clinical variables was developed to facilitate precise risk stratification and personalized TNT decision-making for LARC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.